Doctors have for the first time tested a powerful gene-editing technique in people with cancer. The test, meant to assess only safety, was the first step toward the ultimate goal of editing genes to help a patient’s own immune system to attack cancer. The editing was done by the DNA-snipping tool Crispr. “The good news is that all of them are alive,” said Dr. Edward A. Stadtmauer, the section chief of hematologic malignancies at the University of Pennsylvania Abramson Cancer Center. Some members of the research team, but not Dr. Stadtmauer, are equity holders in Tmunity, as is the University of Pennsylvania.

Source: New York Times November 06, 2019 13:52 UTC